KR20170024129A - 항균제 - Google Patents

항균제 Download PDF

Info

Publication number
KR20170024129A
KR20170024129A KR1020177004886A KR20177004886A KR20170024129A KR 20170024129 A KR20170024129 A KR 20170024129A KR 1020177004886 A KR1020177004886 A KR 1020177004886A KR 20177004886 A KR20177004886 A KR 20177004886A KR 20170024129 A KR20170024129 A KR 20170024129A
Authority
KR
South Korea
Prior art keywords
gly
leu
ala
lys
thr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020177004886A
Other languages
English (en)
Korean (ko)
Inventor
롭 라빈
슈테판 밀러
이브 브리어
쥐도 폴케르트
마르텐 ?막
마르텐 ”U막
Original Assignee
카톨리에케 유니버시테이트 루벤
뤼산도 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 카톨리에케 유니버시테이트 루벤, 뤼산도 아게 filed Critical 카톨리에케 유니버시테이트 루벤
Publication of KR20170024129A publication Critical patent/KR20170024129A/ko
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Disinfection or sterilisation of materials or objects, in general; Accessories therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4723—Cationic antimicrobial peptides, e.g. defensins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2462—Lysozyme (3.2.1.17)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/503—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01017—Lysozyme (3.2.1.17)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
KR1020177004886A 2009-06-26 2010-06-28 항균제 Ceased KR20170024129A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09163953 2009-06-26
EP09163953.4 2009-06-26
PCT/EP2010/059146 WO2010149792A2 (en) 2009-06-26 2010-06-28 Antimicrobial agents

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020127002107A Division KR101711062B1 (ko) 2009-06-26 2010-06-28 항균제

Publications (1)

Publication Number Publication Date
KR20170024129A true KR20170024129A (ko) 2017-03-06

Family

ID=42799668

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020177004886A Ceased KR20170024129A (ko) 2009-06-26 2010-06-28 항균제
KR1020127002107A Active KR101711062B1 (ko) 2009-06-26 2010-06-28 항균제

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020127002107A Active KR101711062B1 (ko) 2009-06-26 2010-06-28 항균제

Country Status (17)

Country Link
US (3) US8906365B2 (https=)
EP (3) EP2445515B1 (https=)
JP (2) JP6034187B2 (https=)
KR (2) KR20170024129A (https=)
CN (2) CN102458452B (https=)
AU (3) AU2010264656B2 (https=)
BR (1) BRPI1015192A2 (https=)
CA (1) CA2764131C (https=)
DK (1) DK2445515T3 (https=)
EA (1) EA037202B1 (https=)
ES (1) ES2579806T3 (https=)
IL (2) IL217124A (https=)
MX (2) MX360300B (https=)
PL (1) PL2445515T3 (https=)
SG (1) SG177370A1 (https=)
SI (1) SI2445515T1 (https=)
WO (1) WO2010149792A2 (https=)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0815484D0 (en) 2008-08-26 2008-10-01 Univ Leuven Kath Antibacterial agents
KR101701890B1 (ko) 2009-06-26 2017-02-02 뤼산도 아게 항균제
DK2445515T3 (en) 2009-06-26 2016-07-04 Univ Leuven Kath antimicrobial agents
SG178440A1 (en) 2009-08-24 2012-04-27 Univ Leuven Kath New endolysin obpgplys
EA037276B1 (ru) * 2010-04-27 2021-03-03 Лисандо Аг Способы устранения или уменьшения бактериальной биопленки
EP2468856A1 (en) * 2010-12-23 2012-06-27 Lysando Aktiengesellschaft Antimicrobial Agents
CN103635584B (zh) 2011-04-12 2017-10-27 冈戈根股份有限公司 嵌合抗菌多肽
US9068204B2 (en) 2013-03-15 2015-06-30 The United States Of America, As Represented By The Secretary Of Agriculture Peptidoglycan hydrolase antimicrobials for eradicating lactobacilli that contaminate and reduce ethanol yields in biofuel fermentation
WO2015070912A1 (en) * 2013-11-14 2015-05-21 Lysando Ag Modified el188 endolysin sequence
WO2015070911A1 (en) * 2013-11-14 2015-05-21 Lysando Ag Modified kz144 endolysin sequence
WO2015121443A1 (en) 2014-02-14 2015-08-20 Lysando Ag Antimicrobial agents
CA2941426C (en) * 2014-04-08 2022-09-27 Lysando Ag Pharmaceutical composition against chronic bacterial infections
AU2015279705B2 (en) * 2014-06-26 2021-04-01 The Rockefeller University Acinetobacter lysins
CN105734029B (zh) * 2014-12-12 2020-09-25 丰益(上海)生物技术研发中心有限公司 磷脂酶抗菌肽
AU2016324307B2 (en) 2015-09-17 2021-10-21 Contrafect Corporation Use of lysin to restore/augment antibacterial activity in the presence of pulmonary surfactant of antibiotics inhibited thereby
CN105175509A (zh) * 2015-10-19 2015-12-23 河南科技学院 一种抗菌肽xyz-1及其应用
CA3014442A1 (en) * 2016-02-29 2017-09-08 Dana-Farber Cancer Institute, Inc. Stapled intracellular-targeting antimicrobial peptides to treat infection
AU2017255962B2 (en) * 2016-04-28 2023-02-23 Lysando Ag Antimicrobial agents against Salmonella bacteria
WO2018100408A1 (en) 2016-11-30 2018-06-07 Sasinapas Co.,Ltd. Modified peptides
AU2017375050B2 (en) * 2016-12-16 2021-07-22 Universidade Do Minho Novel endolysin
US20180208938A1 (en) * 2017-01-23 2018-07-26 Innate Immunity LLC Compositions and Methods for Protecting Plants Against Bacterial Infections
AU2018248060B2 (en) * 2017-04-03 2024-05-23 Sasinapas Co., Ltd. Engineered Gram-negative endolysins
AU2018304230A1 (en) 2017-07-19 2020-02-06 Dana-Farber Cancer Institute, Inc. Stabilized anti-microbial peptides for the treatment of antibiotic-resistant bacterial infections
WO2019155002A1 (en) * 2018-02-08 2019-08-15 Institut Pasteur Anti-prevotella bacteriocin methods and compositions
CN112368376A (zh) * 2018-03-29 2021-02-12 康特拉费克特公司 溶素-抗微生物肽(amp)多肽构建体、溶素、其分离的编码多核苷酸及其用途
WO2020046747A1 (en) * 2018-08-23 2020-03-05 Contrafect Corporation Lysin-antimicrobial peptide (amp) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereof
CN108410840A (zh) * 2018-04-03 2018-08-17 大连理工大学 一种铜绿假单胞菌噬菌体内溶素及其编码基因与应用
JP6979210B2 (ja) * 2018-04-26 2021-12-08 株式会社ニューギン 遊技機
EP3802620A1 (en) * 2018-05-30 2021-04-14 Lysando AG Novel antimicrobial fusion proteins
US11958890B2 (en) 2018-05-30 2024-04-16 Lysando Ag Antimicrobial proteins
WO2021007107A1 (en) * 2019-07-05 2021-01-14 Contrafect Corporation Antimicrobial, bacteriophage-derived polypeptides and their use against gram-negative and acid-fast bacteria
MX2022011291A (es) 2020-03-11 2022-12-08 Telum Therapeutics S L Nueva lisina recombinante y su uso en el tratamiento de infecciones por bacterias gramnegativas.
CA3171721A1 (en) 2020-03-19 2021-09-23 Fritz Eichenseher A stabilized protein of interest
WO2021235876A1 (ko) * 2020-05-22 2021-11-25 주식회사 라이센텍 신규한 폴리펩타이드, 융합 폴리펩타이드, 및 이를 포함하는 그람음성균에 대한 항생제
KR102286544B1 (ko) * 2021-02-10 2021-08-05 주식회사 라이센텍 융합 폴리펩타이드 및 이를 포함하는 그람음성균에 대한 항생제
EP4182334A4 (en) * 2020-07-17 2024-10-16 The University Of Western Australia COMPOSITIONS AND METHODS OF TREATMENT OF CANCER
CN111876400B (zh) * 2020-08-06 2022-05-24 昆明理工大学 一种常温裂解酶Sly和编码此酶的多核苷酸
SK289101B6 (sk) * 2020-12-17 2023-08-09 Ústav molekulárnej biológie Slovenskej akadémie vied, verejná výskumná inštitúcia Antimikrobiálny proteín, antimikrobiálny rekombinantný proteín s lytickými vlastnosťami, expresný vektor, spôsob ich prípravy a použitie
US11548917B1 (en) * 2021-11-24 2023-01-10 Intron Biotechnology, Inc. Antibacterial composition effective in treating gram negative bacterial infections and method for preparing the same
WO2024241070A1 (en) 2023-05-22 2024-11-28 L'oreal Cosmetic composition comprising an endolysin and a polyvinyl alcohol
FR3149202B1 (fr) 2023-06-02 2026-04-10 Oreal Composition cosmétique comprenant une endolysine dérivée de phage de Staphylococcus aureus et une huile.
FR3152395A1 (fr) 2023-08-28 2025-03-07 L'oreal Composition cosmétique comprenant une endolysine dérivée de phage de Staphylococcus aureus et la 4-hydroxyacetophenone
FR3149205B1 (fr) 2023-06-02 2026-04-24 Oreal Composition cosmétique comprenant une endolysine et un agent de charge organique
FR3149204B1 (fr) 2023-06-02 2026-02-13 Oreal Composition cosmétique comprenant une endolysine et un tensioactif non ionique comprenant un résidu carbohydrate
FR3149209B1 (fr) 2023-06-02 2026-04-03 Oreal Composition cosmétique comprenant une endolysine dérivée de phage de Staphylococcus aureus et un alcool aromatique
FR3149208B1 (fr) 2023-06-02 2026-03-20 Oreal Composition cosmétique, notamment aqueuse, comprenant une endolysine et un pullulane
FR3149203B1 (fr) 2023-06-02 2026-03-13 Oreal Composition anhydre comprenant une endolysine et de l’hydroxypropylmethylcellulose et/ou du pullulane
EP4719330A1 (en) 2023-06-02 2026-04-08 L'oreal Cosmetic composition comprising an endolysin derived from a staphylococcus aureus phage and an aromatic alcohol
FR3149206B1 (fr) 2023-06-02 2026-03-13 Oreal Composition cosmétique aqueuse comprenant une endolysine et du tréhalose
FR3149207B1 (fr) 2023-06-02 2026-03-13 Oreal Composition cosmétique comprenant une endolysine et un composé de formule (I)
FR3152394B1 (fr) 2023-08-28 2026-04-24 Oreal Composition cosmétique comprenant une endolysine et des particules d’aérogel de silice hydrophobe
FR3152396A1 (fr) 2023-08-28 2025-03-07 L'oreal Composition cosmétique comprenant une endolysine dérivée de phage de Staphylococcus aureus et un polyhydroxyalcane
FR3152393B1 (fr) 2023-08-28 2026-04-24 Oreal Composition cosmétique comprenant une endolysine dérivée d’un phage de Staphylococcus aureus et une charge minérale
WO2025093666A1 (en) 2023-11-01 2025-05-08 University Of Copenhagen Treatment of lymphoma
CN117534733B (zh) * 2024-01-10 2024-03-29 黑龙江八一农垦大学 抗菌肽cm24、重组基因、乳酸工程菌及其应用
CN118895244B (zh) * 2024-07-23 2025-06-20 浙江自贸区中航生物科技有限责任公司 一种提高nk细胞杀伤活性的多肽及其应用
WO2026052743A1 (en) 2024-09-04 2026-03-12 Micreos Human Health B.V. Reduction of trans-epidermal water loss by a polypeptide with antibacterial properties

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989000194A1 (en) * 1987-07-06 1989-01-12 Louisiana State University Agricultural And Mechan Inhibition of eucaryotic pathogens and neoplasms and stimulation of fibroblasts and lymphocytes with lytic peptides
GB8816693D0 (en) 1988-07-13 1988-08-17 Agricultural & Food Res Viral enzyme & gene
GB2255561B (en) 1991-04-20 1995-06-21 Agricultural & Food Res Lysins from bacteriophages
ATE233817T1 (de) 1992-08-21 2003-03-15 Univ British Columbia Kationische peptide und verfahren zu deren herstellung
ATE198119T1 (de) 1994-09-01 2001-01-15 Novo Nordisk As Eine grundlegende proteinzusammensetzung zur abtötung oder inhibierung mikrobieller zellen
US6503881B2 (en) 1996-08-21 2003-01-07 Micrologix Biotech Inc. Compositions and methods for treating infections using cationic peptides alone or in combination with antibiotics
US5997862A (en) 1997-10-31 1999-12-07 New Horizons Diagnostics Corporation Therapeutic treatment of group A streptococcal infections
US20030113298A1 (en) * 1997-10-31 2003-06-19 Vincent Fischetti Use of bacterial phage associated lysing proteins for the prophylactic and therapeutic treatment of various illnesses
US6428784B1 (en) 1997-10-31 2002-08-06 New Horizons Diagnostics Corp Vaginal suppository for treating group B Streptococcus infection
US6288212B1 (en) * 1998-08-28 2001-09-11 The University Of British Columbia Anti-endotoxic, antimicrobial cationic peptides and methods of use therefor
US5993809A (en) 1998-11-18 1999-11-30 Children's Hospital Medical Center Lysozyme fusion proteins in infections
EP1194570A1 (en) * 1999-06-23 2002-04-10 PPL Therapeutics (Scotland) Limited Fusion proteins incorporating lysozyme
US7338936B2 (en) * 2000-11-28 2008-03-04 House Ear Institute Use of antimicrobial proteins and peptides for the treatment of otitis media and paranasal sinusitis
CA2482995C (en) 2002-04-22 2013-01-29 Dow Global Technologies Inc. Low-cost production of peptides
US7566447B2 (en) * 2003-05-15 2009-07-28 Iogenetics, Llc Biocides
JP2007504810A (ja) * 2003-09-11 2007-03-08 ノボザイムス アクティーゼルスカブ 抗微生物剤の組換え製造
WO2005108563A2 (en) 2004-04-19 2005-11-17 University Of Chicago Peptidoglycan-hydrolyzing protein encoded by bacteriophage n4
US20070207209A1 (en) * 2004-08-27 2007-09-06 Murphy Christopher J Trophic factor combinations for nervous system treatment
US7572602B1 (en) 2004-12-03 2009-08-11 The United States Of America As Represented By The Secretary Of Agriculture Nucleic acid encoding endolysin fusion protein
DE102005040347A1 (de) 2005-08-25 2007-03-01 Profos Ag Verfahren und Mittel zur Anreicherung, Entfernung und zum Nachweis von Listerien
US7943128B2 (en) 2006-03-31 2011-05-17 The University Court Of The University Of St Andrews Anti-microbial compositions comprising a cationic peptide and a glycylglycine endopeptidase
DE102006061002A1 (de) 2006-12-22 2008-06-26 Profos Ag Verfahren und Mittel zur Anreicherung, Entfernung und zum Nachweis von gram-positiven Bakterien
US8586709B2 (en) * 2007-09-25 2013-11-19 Pastoral Greenhouse Research Limited Cell-permeabilising peptides and polypeptides for microbial cells
AU2008328584A1 (en) 2007-11-26 2009-06-04 Plant Bioscience Limited Novel polypeptides having endolysin activity and uses thereof
CA2736062A1 (en) 2008-07-24 2010-01-28 The United State Of America, As Represented By The Secretary Of Agricuure Triple acting antimicrobials that are refractory to resistance development
EP2157100A1 (en) 2008-08-19 2010-02-24 Profos AG Artificial peptidoglycan lysing enzymes and peptidoglycan binding proteins
GB0815484D0 (en) 2008-08-26 2008-10-01 Univ Leuven Kath Antibacterial agents
JP5654493B2 (ja) * 2009-02-03 2015-01-14 アプライド・バイオミメティック・エイ／エス 重合プロテオリポソームを用いたナノ加工膜
WO2010091294A2 (en) 2009-02-05 2010-08-12 The Regents Of The University Of California New targeted antimicrobial moieties
US8383102B2 (en) 2009-05-21 2013-02-26 The United States Of America As Represented By The Secretary Of Agriculture Fusion of peptidoglycan hydrolase enzymes to a protein transduction domain allows eradication of both extracellular and intracellular gram positive pathogens
DK2445515T3 (en) 2009-06-26 2016-07-04 Univ Leuven Kath antimicrobial agents
KR101701890B1 (ko) 2009-06-26 2017-02-02 뤼산도 아게 항균제
SG178440A1 (en) 2009-08-24 2012-04-27 Univ Leuven Kath New endolysin obpgplys
EA037276B1 (ru) 2010-04-27 2021-03-03 Лисандо Аг Способы устранения или уменьшения бактериальной биопленки
WO2014001571A1 (en) 2012-06-29 2014-01-03 Lysando Ag Composition for use in mycobacteria diagnosis

Also Published As

Publication number Publication date
AU2010264656B2 (en) 2016-01-21
CA2764131A1 (en) 2010-12-29
MX360300B (es) 2018-10-29
US20150118731A1 (en) 2015-04-30
EP2445515B1 (en) 2016-04-06
EA037202B1 (ru) 2021-02-18
IL217124A0 (en) 2012-02-29
WO2010149792A3 (en) 2011-02-24
EP3714895A2 (en) 2020-09-30
PL2445515T3 (pl) 2016-10-31
IL250938A0 (en) 2017-04-30
KR20120095345A (ko) 2012-08-28
CN105440139A (zh) 2016-03-30
SI2445515T1 (sl) 2016-08-31
SG177370A1 (en) 2012-02-28
US20120189606A1 (en) 2012-07-26
EP2445515A2 (en) 2012-05-02
CA2764131C (en) 2022-05-10
EP3058950A3 (en) 2016-10-12
CN102458452B (zh) 2015-12-02
JP2017008033A (ja) 2017-01-12
CN105440139B (zh) 2019-08-13
EP3058950A2 (en) 2016-08-24
AU2018201931B2 (en) 2019-08-15
KR101711062B1 (ko) 2017-02-28
US11052137B2 (en) 2021-07-06
US10137175B2 (en) 2018-11-27
EA201270079A1 (ru) 2012-06-29
WO2010149792A2 (en) 2010-12-29
ES2579806T3 (es) 2016-08-16
DK2445515T3 (en) 2016-07-04
US8906365B2 (en) 2014-12-09
IL250938B (en) 2019-12-31
US20190209663A1 (en) 2019-07-11
JP2012530509A (ja) 2012-12-06
CN102458452A (zh) 2012-05-16
AU2010264656A1 (en) 2011-12-08
EP3714895A3 (en) 2020-11-25
IL217124A (en) 2017-03-30
EP3058950B1 (en) 2020-03-04
MX2011013288A (es) 2012-02-28
JP6034187B2 (ja) 2016-11-30
AU2016202296A1 (en) 2016-05-12
AU2018201931A1 (en) 2018-05-31
AU2016202296B2 (en) 2017-12-21
BRPI1015192A2 (pt) 2019-09-17
HK1169311A1 (zh) 2013-01-25

Similar Documents

Publication Publication Date Title
AU2016202296B2 (en) Antimicrobial Agents
EP2655610B1 (en) Antimicrobial agents
CN102575240B (zh) 新的细胞内溶素OBPgpLYS
CN102197132B (zh) 抗微生物剂
JP2016208985A (ja) バイオフィルムの低減方法
JP2014500714A (ja) 新規エンドリシン
HK1224571A1 (en) Antimicrobial agents
HK1224571A (en) Antimicrobial agents
HK1224571B (en) Antimicrobial agents
HK1169311B (en) Antimicrobial agents
HK1190430B (en) Antimicrobial agents
HK1190430A (en) Antimicrobial agents

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20170221

Application number text: 1020127002107

Filing date: 20120126

PG1501 Laying open of application
A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20170323

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20170621

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20180523

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20170621

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

X091 Application refused [patent]
AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20180523

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20171221

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20170323

Comment text: Amendment to Specification, etc.

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20180920

Patent event code: PE09021S01D

AMND Amendment
PX0601 Decision of rejection after re-examination

Comment text: Decision to Refuse Application

Patent event code: PX06014S01D

Patent event date: 20190729

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20190320

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20180920

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20180822

Comment text: Decision to Refuse Application

Patent event code: PX06011S01I

Patent event date: 20180523

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20171221

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20170621

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20170323

X601 Decision of rejection after re-examination
J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

Patent event date: 20191028

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20190729

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Patent event date: 20180523

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20200515

Appeal identifier: 2019101003555

Request date: 20191028

J301 Trial decision

Free format text: TRIAL NUMBER: 2019101003555; TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20191028

Effective date: 20200515

PJ1301 Trial decision

Patent event code: PJ13011S01D

Patent event date: 20200515

Comment text: Trial Decision on Objection to Decision on Refusal

Appeal kind category: Appeal against decision to decline refusal

Request date: 20191028

Decision date: 20200515

Appeal identifier: 2019101003555